Tirzepatide is a synthetic dual-agonist peptide engineered to engage both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. For research teams comparing single-, dual-, and tri-receptor incretin signaling, it offers a distinct, imbalanced pharmacological profile. Puritide Research supplies Tirzepatide as a high-purity, research-use-only material, synthesized for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›Tirzepatide 10 mg Vial
- ›Tirzepatide 20 mg Vial
- ›Tirzepatide 30 mg Vial
- ›Tirzepatide 50 mg Vial
- ›Tirzepatide 100 mg Vial
Product Specifications
- Application
- Dual incretin receptor research (GIP / GLP-1)
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- C225H348N48O68
- PubChem SID
- 156588324
- CAS Number
- 2023788-19-2
- Molecular Weight
- ~4813.45 g/mol
- Synonyms
- Tirzepatide, LY3298176, GIP/GLP-1 dual agonist, twincretin, tirzepatide acetate
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is Tirzepatide?
Tirzepatide (LY3298176) is a synthetic 39-residue peptide engineered by grafting GLP-1 activity onto a GIP-based backbone, producing a single molecule that engages two incretin receptor systems: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). A fatty-acid moiety promotes reversible albumin binding, which is associated with extended molecular stability in experimental systems.
In laboratory settings, Tirzepatide is used to study coordinated incretin signaling, receptor pharmacology, and downstream intracellular cascades. It is described in the literature as an imbalanced or biased dual agonist, engaging GIPR with affinity comparable to native GIP while binding GLP-1R more weakly than native GLP-1, a feature that makes it a valuable tool for dissecting receptor-specific contributions.
Present understanding derives from in vitro assays, animal models, and published clinical research. Findings should be interpreted within their experimental context and not treated as established outcomes for any use supplied by Puritide Research. Tirzepatide is supplied strictly for laboratory use and is not approved for human or veterinary application.
Puritide Research supplies GLP-2 (TZ) strictly for laboratory research use. Not for human or veterinary use.
Research Use Only
